These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 24176496)

  • 21. Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccine.
    Bouckenooghe A; Bailleux F; Feroldi E
    Hum Vaccin Immunother; 2019; 15(1):72-79. PubMed ID: 30230947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine.
    Beasley DW; Li L; Suderman MT; Guirakhoo F; Trent DW; Monath TP; Shope RE; Barrett AD
    Vaccine; 2004 Sep; 22(27-28):3722-6. PubMed ID: 15315852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children.
    Feroldi E; Capeding MR; Boaz M; Gailhardou S; Meric C; Bouckenooghe A
    Hum Vaccin Immunother; 2013 Apr; 9(4):889-97. PubMed ID: 23442823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of an inactivated Japanese encephalitis vaccine (JE-VAX) in humans over 20 years at USAMRIID: using PRNT50 as an endpoint for immunogenicity.
    Reisler RB; Danner DK; Gibbs PH
    Vaccine; 2010 Mar; 28(12):2436-41. PubMed ID: 20060946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence of Wild-Type Japanese Encephalitis Virus Strains Cross-Neutralization 5 Years After JE-CV Immunization.
    Feroldi E; Boaz M; Yoksan S; Chokephaibulkit K; Thisyakorn U; Pancharoen C; Monfredo C; Bouckenooghe A
    J Infect Dis; 2017 Jan; 215(2):221-227. PubMed ID: 27815383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Fischer M; Lindsey N; Staples JE; Hills S;
    MMWR Recomm Rep; 2010 Mar; 59(RR-1):1-27. PubMed ID: 20224546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51.
    Eder S; Dubischar-Kastner K; Firbas C; Jelinek T; Jilma B; Kaltenboeck A; Knappik M; Kollaritsch H; Kundi M; Paulke-Korinek M; Schuller E; Klade CS
    Vaccine; 2011 Mar; 29(14):2607-12. PubMed ID: 21288804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is a booster dose necessary in children after immunization with live attenuated Japanese encephalitis vaccine?
    Choi UY; Lee SY; Kim KH; Kim DS; Choi KM; Cha SH; Kang JH
    J Trop Pediatr; 2013 Oct; 59(5):423-5. PubMed ID: 23764540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.
    Chanthavanich P; Limkittikul K; Sirivichayakul C; Chokejindachai W; Hattasingh W; Pengsaa K; Surangsrirat S; Srisuwannaporn T; Kaewma B; Yoksan S; Jun G; Zhumu B
    Hum Vaccin Immunother; 2018 Apr; 14(4):900-905. PubMed ID: 29227177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study on the protective efficacy of SA14-14-2 attenuated Japanese encephalitis against different JE virus isolates circulating in China.
    Liu X; Yu Y; Li M; Liang G; Wang H; Jia L; Dong G
    Vaccine; 2011 Mar; 29(11):2127-30. PubMed ID: 21237278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced neutralizing antibody titer against genotype I virus in swine immunized with a live-attenuated genotype III Japanese encephalitis virus vaccine.
    Fan YC; Chen JM; Chen YY; Lin JW; Chiou SS
    Vet Microbiol; 2013 May; 163(3-4):248-56. PubMed ID: 23415032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Japanese Encephalitis Vaccine From India Induces Durable and Cross-protective Immunity Against Temporally and Spatially Wide-ranging Global Field Strains.
    Singh A; Mitra M; Sampath G; Venugopal P; Rao JV; Krishnamurthy B; Gupta MK; Sri Krishna S; Sudhakar B; Rao NB; Kaushik Y; Gopinathan K; Hegde NR; Gore MM; Krishna Mohan V; Ella KM
    J Infect Dis; 2015 Sep; 212(5):715-25. PubMed ID: 25601942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistence of the immune response after vaccination with the Japanese encephalitis vaccine, IXIARO® in healthy adults: A five year follow-up study.
    Taucher C; Kollaritsch H; Dubischar KL
    Vaccine; 2019 May; 37(19):2529-2531. PubMed ID: 30962094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of Vero Cell Culture-derived Japanese Encephalitis Vaccine in Pediatric and Young Hematopoietic Stem Cell Transplantation Recipients.
    Assawawiroonhakarn S; Apiwattanakul N; Pakakasama S; Hongeng S; Anurathapan U; Yoksan S; Klinmalai C; Sae-Chew P; Techasaensiri C
    Pediatr Infect Dis J; 2021 Mar; 40(3):264-268. PubMed ID: 33427799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunizing children aged 9 to 15 months with live attenuated SA14-14-2 Japanese encephalitis vaccine in Thailand.
    Chotpitayasunondh T; Sohn YM; Yoksan S; Min J; Ohrr H
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S195-203. PubMed ID: 22043776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines--report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies.
    Ferguson M; Johnes S; Li L; Heath A; Barrett A
    Biologicals; 2008 Mar; 36(2):111-6. PubMed ID: 17892945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes.
    Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
    Clin Infect Dis; 2013 Jan; 56(2):267-70. PubMed ID: 23074319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralizing antibody persistence in pediatric travelers from non-JE-endemic countries following vaccination with IXIARO® Japanese encephalitis vaccine: An uncontrolled, open-label phase 3 follow-up study.
    Taucher C; Barnett ED; Cramer JP; Eder-Lingelbach S; Jelinek T; Kadlecek V; Kiermayr S; Mills DJ; Pandis D; Reiner D; Dubischar KL
    Travel Med Infect Dis; 2020; 34():101616. PubMed ID: 32156630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study.
    Cramer JP; Dubischar K; Eder S; Burchard GD; Jelinek T; Jilma B; Kollaritsch H; Reisinger E; Westritschnig K
    Vaccine; 2016 Aug; 34(38):4579-4585. PubMed ID: 27460550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.